With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
This one hour session will touch on the legal framework of recreational and medicinal cannabis in Switzerland and provide a high-level overview of the newest developments, the challenges, as well as the opportunities in Switzerland’s dynamic cannabis market.
Those already in the cannabis industry and those looking to get into it will get a chance to learn more about newest adult-use markets in the country, how they compare to one another, and what we can anticipate as these new opportunities take shape.
In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
The purpose of this webinar is to provide a clear overview of the current regulatory landscape in France on both medical cannabis and wellness hemp/CBD and to answer some frequently asked questions in order to provide some practical tips as to what can be done or not and what to expect in the near future.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.